Pembrolizumab monotherapy for advanced chordoma.

作者信息

Hu Xianglin, Wang Chunmeng, Huang Wending, Barber Sean M, Yan Wangjun

机构信息

Department of Musculoskeletal Oncology, Spine Tumor Center, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China.

Department of Neurosurgery, Houston Methodist Neurological Institute, Houston Methodist Hospital, Houston, TX, USA.

出版信息

Lancet Oncol. 2023 Oct;24(10):e399. doi: 10.1016/S1470-2045(23)00395-9.

DOI:10.1016/S1470-2045(23)00395-9

PMID:37797637

Abstract

摘要

相似文献

Pembrolizumab monotherapy for advanced chordoma.

Lancet Oncol. 2023 Oct;24(10):e399. doi: 10.1016/S1470-2045(23)00395-9.

Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer.在程序性死亡受体1（PD-L1）表达的非小细胞肺癌中，帕博利珠单抗单药治疗进展后加用铂类化疗的疾病反应情况。

J Thorac Oncol. 2018 Aug;13(8):e135-e136. doi: 10.1016/j.jtho.2018.02.031.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。

Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.

Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores.帕博利珠单抗单药治疗与化疗在不同 PD-L1 肿瘤比例评分的非小细胞肺癌中的成本效益分析。

Lung Cancer. 2019 Oct;136:98-101. doi: 10.1016/j.lungcan.2019.08.028. Epub 2019 Aug 26.

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.对于 PD-L1 高表达的晚期非小细胞肺癌患者的一线治疗：帕博利珠单抗或帕博利珠单抗联合化疗。

J Immunother Cancer. 2019 May 3;7(1):120. doi: 10.1186/s40425-019-0600-6.

Brief Report on Use of Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis.帕博利珠单抗联合或不联合化疗治疗晚期肺癌的真实世界分析简要报告

Clin Lung Cancer. 2023 Jun;24(4):362-365. doi: 10.1016/j.cllc.2023.01.011. Epub 2023 Feb 8.

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.KEYNOTE-024 更新分析：PD-L1 肿瘤比例评分≥50%的晚期非小细胞肺癌的帕博利珠单抗对比铂类化疗

J Clin Oncol. 2019 Mar 1;37(7):537-546. doi: 10.1200/JCO.18.00149. Epub 2019 Jan 8.

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression.帕博利珠单抗联合化疗与帕博利珠单抗单药治疗的失败时间比较：高 PD-L1 表达的 NSCLC 患者的连续分析。

Cancer Immunol Immunother. 2022 Mar;71(3):737-746. doi: 10.1007/s00262-021-03029-9. Epub 2021 Aug 14.

First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.在程序性死亡受体配体1（PD-L1）表达≥50%的非小细胞肺癌患者中，一线使用帕博利珠单抗联合或不联合铂类双药化疗。

Future Oncol. 2021 Aug;17(23):3007-3016. doi: 10.2217/fon-2020-1202. Epub 2021 Jun 22.

Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.帕博利珠单抗单药治疗与化疗用于既往未治疗的晚期非小细胞肺癌的成本效益分析。

J Med Econ. 2020 Sep;23(9):952-960. doi: 10.1080/13696998.2020.1775620. Epub 2020 Jun 22.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验